LNAINasdaqPharmaceutical PreparationsFiscal year ends June 30
Lunai Bioworks Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Oct 13, 2026
$0.47−0.21 (-30.63%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Lunai Bioworks Inc. revenue by segment
By business segment
| Operating income | Q3 26 | Q4 25 | Q3 25 | Q1 25 | YoY |
|---|---|---|---|---|---|
| RENC [Member] | – | – | – | -$48.38M | – |
| RENB [Member] | – | – | – | -$4.96M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Lunai Bioworks's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.